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Background: Poxviruses contain several virulence factors with no identifiable cellular homologues.
Results:Vaccinia virus immunomodulatory proteinA49 adopts the same fold as cellular and viral Bcl-2 family proteins but does
not share their function.
Conclusion: Vaccinia virus Bcl-2-like proteins resemble each other structurally but have divergent functions.
Significance: Viruses hijack protein scaffolds and evolve them to subvert host-cell immunity.
Vaccinia virus (VACV) encodes several proteins that inhibit
activation of the proinflammatory transcription factor nuclear
factorB (NF-B). VACVproteinA49 prevents translocation of
NF-B to the nucleus by sequestering cellular-TrCP, a protein
required for the degradation of the inhibitor ofB.A49 does not
share overall sequence similarity with any protein of known
structure or function. We solved the crystal structure of A49
from VACV Western Reserve to 1.8 Å resolution and showed,
surprisingly, that A49 has the same three-dimensional fold as
Bcl-2 family proteins despite lacking identifiable sequence sim-
ilarity.Whereas Bcl-2 family members characteristically modu-
late cellular apoptosis, A49 lacks a surface groove suitable for
binding BH3 peptides and does not bind proapoptotic Bcl-2
family proteins Bax or Bak. The N-terminal 17 residues of A49
do not adopt a single well ordered conformation, consistent
with their proposed role in binding -TrCP. Whereas pairs of
A49 molecules interact symmetrically via a large hydrophobic
surface in crystallo, A49 does not dimerize in solution or in cells,
and we propose that this hydrophobic interaction surface may
mediate binding to a yet undefined cellular partner. A49 repre-
sents the eleventhVACVBcl-2 family protein and, despite these
proteins sharing very low sequence identity, structure-based
phylogenetic analysis shows that all poxvirus Bcl-2 proteins are
structurally more similar to each other than they are to any cel-
lular or herpesvirusBcl-2 proteins. This is consistentwithdupli-
cation and diversification of a single BCL2 family gene acquired
by an ancestral poxvirus.
Vaccinia virus (VACV),3 the vaccine used to eradicate small-
pox, has a large dsDNA genome encoding 200 ORFs (1).
About half of these genes are not essential for virus replication
but rather affect the virulence and host range of the virus by
counteracting the host immune response to infection (2).
Understanding how VACV modulates the host immune
response can yield unexpected insights into cellular innate
immunity (3) and is essential to fully exploit the promise of
VACV as a safe vaccine vector (4).
VACVA49 is a virulence factor that inhibits the activation of
the host transcription factor NF-B (5). NF-B activity is stim-
ulated by extrinsic proinflammatory signals, such as interleukin
1 or tumornecrosis factor, and by intracellular signals, such as
the recognition of foreign cytoplasmic RNA by retinoic acid-
inducible gene I-like helicases (6). NF-B is usually retained,
inactive, in the cytoplasm via an interaction with the inhibitor
ofB (IB). Uponproinflammatory stimulation, IB is phos-
phorylated by IB kinases and subsequently ubiquitinated and
degraded. This allows NF-B to translocate to the nucleus and
promote transcription of cytokines and chemokines, including
interferon , that promote inflammation and an anti-viral state
in surrounding cells (7). A49 inhibits the ubiquitination of IB
by binding -TrCP, a component of the Skp1Cullin1F-box
protein (SCF)-TrCP ubiquitin E3 ligase complex. Mutational
analysis suggested that it does so via anN-terminal peptide that
binds the -propeller domain of -TrCP in an extended fash-
ion, similar to the bindingmode observed for-catenin (8), and
thereby blocks binding of IB to the same site (5). The impor-
tance of inhibiting NF-B activation to the virus is underscored
by the fact that VACVhas at least 10 proteins that interrupt this
pathway and deletion of any of these genes attenuates the virus
(9). Inhibiting the degradation of IB appears to be of partic-
ular importance for poxvirus virulence; ectromelia virus lacks
an A49 homologue but it contains EVM005, an ankyrin family
protein that contains an F-box domain and is thought to com-
* This work was supported by Wellcome Trust Principal Research Fellowship
090315 (to G. L. S.), Sir Henry Dale Fellowship 098406/Z/12/Z, jointly
funded by the Wellcome Trust and the Royal Society (to S. C. G.), and
United Kingdom Medical Research Council Grant G1000099 (to David
Stuart).
Author’s Choice—Final version free via Creative Commons CC-BY license.
□S This article contains supplemental PDB files.
Theatomic coordinatesandstructure factors (codes4D5R, 4D5S, and4D5T)have
been deposited in the Protein Data Bank (http://wwpdb.org/).
1 Present Address: Dept. of Microbial and Cellular Sciences, University of Sur-
rey, Guildford GU2 7XH, United Kingdom.
2 To whom correspondence should be addressed. E-mail: scg34@cam.ac.uk.
3 The abbreviations used are: VACV, vaccinia virus; IKK, IB kinase ; MALS,
multiangle light scattering; MYXV, myxoma virus; SEC, size exclusion chro-
matography; WR, Western Reserve.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 290, NO. 10, pp. 5991–6002, March 6, 2015
Author’s Choice © 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
MARCH 6, 2015•VOLUME 290•NUMBER 10 JOURNAL OF BIOLOGICAL CHEMISTRY 5991
 by guest on A
ugust 21, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
pete with the F-box region of -TrCP for binding to Skp1, thus
preventing IB ubiquitination and degradation (10).
Previous studies have identified that many poxvirus immu-
nomodulatory proteins, including 10 VACV proteins, share
structural similarity with the Bcl-2 (B-cell lymphoma 2) family
of cellular proteins despite lacking identifiable sequence simi-
larity (11–16). Cellular members of the Bcl-2 family generally
share four Bcl-2 homology domains (BH1–BH4) in their pri-
mary sequence, and they are key regulators of apoptosis (17).
Whereas poxvirus Bcl-2-like proteins F1,M11, andN1 all act to
inhibit apoptosis, other poxvirus Bcl-2 family proteins have
instead evolved to inhibit activation of the transcription factors
NF-B or IRF3 (9, 13). Of particular interest is VACV protein
N1, which inhibits both apoptosis and NF-B via two distinct
molecular surfaces; inhibition of apoptosis is mediated via a
hydrophobic surface groove, whereas inhibition of NF-B is
disrupted by mutating a surface on the opposite face of the
protein that mediates N1 dimerization both in solution and in
cells (18).
Homologues of A49 are found only in a subset of orthopox-
viruses (5). Aside from a stretch of six amino acids at its N
terminus, the 18.8-kDa A49 protein and its orthologues in
other orthopoxviruses share no identifiable sequence identity
with any protein of known structure or function. To further
investigate the function of A49, we solved its structure to 1.8 Å
resolution by x-ray crystallography. Unexpectedly, the struc-
ture showed that A49 possesses a Bcl-2-like fold despite not
sharing sequence identitywith known cellular or poxvirus Bcl-2
family proteins. Structure-based phylogenetic analysis shows
that A49 is most closely related to other poxvirus Bcl-2-like
proteins, consistent with its evolution from an ancestral poxvi-
rus BCL2 family gene by means of gene duplication and
diversification.
EXPERIMENTAL PROCEDURES
Expression Vectors—For bacterial expression, A49R from
VACV Western Reserve (WR) was amplified using KOD HiFi
DNA polymerase (Novagen) with forward primer 5-AGGAGA-
TATACCATGGATGAAGCATATTACTCTGGCAAC-3 and
reverse primer 5-GTGATGGTGATGTTTCAAATATCGTTC-
GCGGATATCATTAG-3 and cloned into pOPINE (19), adding
aC-terminalLysHis6 fusion tag (full-lengthA49).A truncatedA49
construct lacking residues 1–12 (A49 12) was cloned into
pOPTnH, a pOPT (20) vector modified to encode a C-terminal
LysHis6 tag, following amplification using Platinum TaqDNA
polymerase high fidelity (Invitrogen) with forward primer 5-
GGAAGTCATATGGTACTCGGATACGTGTCCGATATGC-
ATAC-3 and reverse primer 5-GGAAGTGGATCCCA-
AATATCGTTCGCGGATATCATTAGACAATTG-3 contain-
ing NdeI and BamHI restriction sites (underlined), respectively.
C-terminally His6-tagged N1 in pET24a was described previously
(21).
For mammalian expression, VACVWR A49R was amplified
using KOD HiFi DNA polymerase (Novagen) with forward
primer 5-AAGTTCTGTTTCAGGGCCCGGATGAAGCAT-
ATTACTCTGGCAAC-3 and reverse primer 5-ATGGT-
CTAGAAAGCTTTACAAATATCGTTCGCGGATATCAT-
TAG-3. The PCR product was cloned into pOPINF (19),
adding an N-terminal His6 tag and rhinovirus 3C protease site
(nHis-A49). nTAP-A49, Myc- and TAP--TrCP (5), FLAG-
B14 (22), FLAG-M11 (13), and HA-Bak and HA-Bax (12) have
all been described.
Protein Production andCharacterization—N1was expressed
and purified as described previously (12). Full-length A49
and A49 12 were expressed in Escherichia coli Rosetta2-
(DE3)pLysS (Novagen). Bacteria were grown in 2TYmedium
to an A600 of 0.8 at 37 °C and cooled to 22 °C, and protein
expression was induced by the addition of 0.2 mM isopropyl
-D-thiogalactopyranoside. After 16 h, cells were harvested by
centrifugation at 5000 g for 15 min at 4 °C, and the pellet was
stored at20 °C until required.
Cells were thawed and resuspended in 20 mM Tris, 500 mM
NaCl, 30 mM imidazole, 1.4 mM -mercaptoethanol, 0.05%
Tween 20, pH 7.5, supplemented with 400 units of bovine
DNase I (Sigma-Aldrich) and 200 l of EDTA-free protease
inhibitor mixture (Sigma-Aldrich) before lysis at 165.5 MPa
using a TS series cell disruptor (Constant Systems) and centri-
fugation at 40,000  g for 30 min at 4 °C. Cleared lysate was
incubated with Ni2-NTA-agarose (Qiagen) for 1 h at 4 °C, the
beads were washed, and the bound protein eluted in 20 mM
Tris, 500 mMNaCl, 250 mM imidazole, pH 7.5, before injection
onto a Superdex 75 16/600 size exclusion chromatography
(SEC) column (GE Healthcare) equilibrated in 20 mM Tris, pH
7.6, 200 mM NaCl, 2 mM DTT (SEC buffer). Purified proteins
were concentrated, snap-frozen in liquid nitrogen, and stored
at80 °C until required.
Multiangle light scattering (MALS) experiments were per-
formed at room temperature immediately after SEC at a flow
rate of 0.5ml/min by inlinemeasurement of static light scatter-
ing (DAWN 8, Wyatt Technology), differential refractive
index (Optilab T-rEX,Wyatt Technology), and 280 nm absorb-
ance (Agilent 1260UV, Agilent Technologies). Samples (100l
of 11.6, 4.1, or 1.2mg/ml full-lengthA49; 13.5, 4.7, or 1.4mg/ml
A49 12; and 10.0, 3.5, or 1.0 mg/ml N1) were injected onto an
analytical Superdex 75 10/300 gel filtration column (GE
Healthcare) equilibrated in SEC buffer. Molar masses were cal-
culated using ASTRA 6 (Wyatt Technology).
Crystallization, Structure Solution, Refinement, and Anal-
ysis—All crystals were grown by sitting drop vapor diffusion
(23) and snap-cryocooled by immersion in liquid nitrogen. Full-
length A49 (100 nl at 9.5 mg/ml) was mixed with 100 nl of
reservoir solution and equilibrated at 21 °C against 95-l reser-
voirs comprising 25% (w/v) PEG 3350, 0.2 M ammonium sul-
fate, and 0.1 M Tris, pH 9.5. Cryoprotection was achieved by
quickly sweeping the crystal through a reservoir supplemented
with 20% (v/v) glycerol. A4912 (1l at 25.0mg/ml)wasmixed
with 1 l of reservoir solution and equilibrated at 20 °C against
500-l reservoirs containing 0.1 MHEPES, pH 7.5, 1.6 M ammo-
nium sulfate, and 1.5% (v/v) PEG 400. Crystals were cryopro-
tected by passage through 2 l of perfluoropolyether oil
(Hampton Research) that had been overlaid onto the mother
liquor. Because the presence of ammonium sulfate in the
mother liquor prevented efficient heavy atom derivatization,
ammonium sulfate was substituted for sodium malonate (24),
and A49 12 crystals were grown by mixing 2 l of protein
(20–21mg/ml) with 2l of reservoir solution and equilibrating
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at 20 °C against 500-l reservoirs containing 1.3–1.5 M sodium
malonate, pH 6.8, 1% (v/v) PEG 400, and 4–10% (v/v) glycerol,
the best crystals being obtainedwhen the reservoir was overlaid
with 100 l of a 1:1 mixture of paraffin and silicone oil (Molec-
ular Dimensions). After crystals had grown, 1l of a 1:100 dilu-
tion of a saturated potassium dicyanoaurate(I) (KAu(CN)2)
solution was added to selected drops, and crystals were incu-
bated for 6 days. Crystals were cryoprotected by brief immer-
sion in 2.1 M sodium malonate, 1% (v/v) PEG 400, and 5% (v/v)
glycerol.
Diffraction data were collected at 100 K on European Syn-
chrotron Radiation Facility beamline ID14-2 and processed
with HKL2000 (full-length A49) or on Diamond Light Source
beamline I04-1 and processed with XDS and XSCALE (25), as
implemented by xia2 (26) (A49 12). The structure of A49
12 was solved by single-wavelength anomalous dispersion
analysis of a potassium dicyanoaurate(I) derivative using the
autoSHARP (27) structure solution pipeline. Eight gold sites
were identified with occupancy ranging from 0.88 to 0.18.
autoSHARP implemented ARP/wARP (28) to build the initial
model that was manually improved with COOT (29) and
refined using Refmac5 (30). The resultant model was used to
solve the structure of A49 12 grown in the sodium malonate
condition by molecular replacement with MOLREP (31). This
model was manually improved with COOT (29) and refined
using Refmac5 (30) with one translation-libration-screw aniso-
tropic displacement group per molecule and local non-crystal-
lographic symmetry restraints. The structures of A4912 crys-
tallized in the ammonium sulfate condition and of full-length
A49 were solved by molecular replacement withMOLREP (31)
and PHASER (32), respectively, using the A49 12 sodium
malonate structure as a search model and were refined using
Refmac5 as detailed above. The stereochemistry of all struc-
tures was assessed and improved using COOT, theMolProbity
Web server (33), and WHAT_CHECK (34).
A representative set of proteins with the Bcl-2 fold were
selectedwith the assistance of the PfamWeb server (35).Where
multiple structureswere available for one protein, crystal struc-
tures determined at the highest resolution were selected.
Where crystal structures hadmultiple molecules per asymmet-
ric unit, LSQMAN (36) was used to select the molecule that
could be superposed on all others with the lowest C atom root
mean square deviation. For NMR ensembles, the well ordered
“core” of the most representative member of the ensemble was
selected in consultationwith theOLDERADOWeb server (37).
VACV protein F1, which exists as a domain-swapped dimer
both in solution and in crystallo (15), was excluded from the
analysis. The structural core of the Bcl-2 fold was identified by
iterative determination of maximal equivalent substructures,
structures were superposed onto this minimal Bcl-2 core, and
the resultant superpositions were scored to generate a phyloge-
netic relationship based on structural equivalence using HSF
as described previously (38). Clustering of equivalent sub-
structures and the structure-based phylogenetic tree were
visualized using Dendroscope (39). Sequence figures were
generate with ALINE (40), molecular graphics were gener-
ated using PyMOL (Schroedinger LLC), and images were
assembled using Inkscape.
Tissue Culture and Viruses—CV-1 and HEK293T cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen) supplemented with 10% heat-treated (56 °C, 1 h)
FBS (Harlan Sera-Lab), 50 IU/ml penicillin, and 50g/ml strep-
tomycin (Invitrogen) at 37 °C in a humidified 5% CO2
atmosphere.
To generate vA49-cTAP, the A49RORF plus 213 bp upstream
was amplified from VACV WR genomic DNA using oligonu-
cleotides 5-GTAGGTACCAACAAAAGGTATTACAAG-
AAT-3 and 5-GTAGCGGCCGCCAAATATCGTTCGCGG-
ATATC-3, containing KpnI and NotI restriction sites (under-
lined), respectively. The PCR fragment was cloned into a
modified pUC13 plasmid upstream of a TAP tag comprising
two copies of the streptavidin binding sequence (Strep-tag II)
followed by one FLAG epitope (41). The modified pUC13 also
contains E. coli guanylphosphoribosyl transferase fused in
frame with enhanced GFP under the control of a VACV pro-
moter (42). The right-flanking region of A49R was amplified
using oligonucleotides 5-GTACCGCGGAAATATTAAAAA-
AAAATA-3 and 5-TCTAGACGGATTTCTGTGTTCTCT-
TTGAAG-3, containing SacII and XbaI restriction sites
(underlined), respectively, and was cloned downstream of the
TAP tag to form pA49vTAP. vA49-cTAP was made by tran-
sient dominant selection (43) after infection of CV-1 cells with
vA49 (5) and transfection with pA49vTAP as described pre-
viously (5). VACV WR containing a C-terminally HA-tagged
B14R (vB14-HA) was described previously (22).
Co-immunoprecipitation and Immunoblotting—HEK293T
cells were transfected using the calcium phosphate method.
Briefly, cells were seeded in 10-cm dishes to reach 50% density
after 24 h, at which time the medium was refreshed and cells
were allowed to rest for 20min. DNA (5g) was incubatedwith
50l of 2.5 M CaCl2 and sterile water to a final volume of 500l
for 20 min at room temperature. An equal volume of 280 mM
NaCl, 10 mM KCl, 1.5 mM Na2HPO4, 12 mM glucose, 50 mM
HEPES, pH 7.05, was added, and the mixture was incubated for
a further 15 min. The mixture was dropped carefully onto the
cells, and the dishes were swirled gently to distribute it evenly.
After 24 h, the medium was removed, and cells were infected
(or mock-infected) with the indicated viruses in fresh DMEM
with 2% FBS plus penicillin and streptomycin.
To test binding of A49 to proapoptotic Bcl-2 proteins, cells
were infected at a multiplicity of infection of 5 for 6 h before
harvesting and washing twice with cold PBS. Cells were lysed
with CHAPS buffer (20 mM Tris, pH 8, 137 mM NaCl, 2% (w/v)
CHAPS, 1 mM EDTA, pH 8, and protease inhibitors (Roche
Applied Science)). Lysates were treated with benzonase (Nova-
gen) for 30 min, cleared, and then incubated with anti-FLAG
M2 affinity resin (Sigma-Aldrich) for 16 h at 4 °C. After four
washes with CHAPS buffer, proteins were boiled off of the
beads in 2 SDS-PAGE loading buffer and analyzed by SDS-
PAGE and immunoblotting.
To test for A49 self-association, cells were infected at a mul-
tiplicity of infection of 2 (multiplicity of infection of 1.5 for each
viruswhen co-infecting) for 16 h before harvesting andwashing
with cold PBS. Cells were lysed with immunoprecipitation
buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 10 mM CaCl2, 0.1%
(v/v) Triton X-100, 10% (v/v) glycerol, and protease inhibitors
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(Roche Applied Science)). Cleared lysates were incubated with
anti-FLAG M2 affinity resin for 16 h at 4 °C. The resin was
washed four times with immunoprecipitation buffer before
proteins were boiled off of the beads in 2 SDS-PAGE loading
buffer and analyzed by SDS-PAGE and immunoblotting.
Following SDS-PAGE, proteins were transferred onto nitro-
cellulose membranes and immunoblotted using the Trans-Blot
semidry transfer system (Bio-Rad) as per the manufacturer’s
instructions. Primary antibodies used recognized tubulin
(clone DM1A, Upstate Biotechnology), FLAG (F7425, Sigma-
Aldrich), HA (mm2-101p (Biolegend) and H6908 (Sigma-
Aldrich)),His6 (34670,Qiagen), andMyc (9B11,Cell Signaling).
The antibody against D8 (AB1.1) was described previously (44).
Immunoblots were visualized using an Odyssey scanner (LI-
COR Biosciences), except for tubulin (Fig. 2), Myc--TrCP
(Fig. 3), andHA (Figs. 2 and 3), where enhanced chemilumines-
cence was used.
RESULTS
Crystal Structure Reveals That A49 Adopts the Bcl-2 Fold—
Crystallization trials of full-length VACV A49 yielded just two
crystals in a single crystallization condition after 4 months of
equilibration. Diffraction data were recorded to 3.0 Å resolu-
tion (full-length A49; Table 1) but, because A49 does not share
identifiable sequence similarity with any proteins of known
structure, it was not possible to solve the structure bymolecular
replacement, and repeated attempts to reproduce these crystals
were unsuccessful, frustrating attempts to solve the structure
by experimental methods. Previous work had shown that the
N-terminal 12 amino acids of A49 are essential for its interac-
tionwith-TrCP and share similaritywith the-TrCP-binding
sequence of -catenin (5). The residues of -catenin that bind
-TrCPhave an extended conformation (8), suggesting that the
equivalent residues of A49 may be poorly ordered and thus
inhibiting crystallization. A truncated form of A49 lacking the
N-terminal 12 amino acids (A49 12) was thus expressed and
purified. It crystallized readily in two distinct conditions, and
diffraction data were recorded to 1.8–1.9 Å resolution (A49
12 ammonium sulfate and A49 12 sodium malonate; Table
1). The structure was solved by single wavelength anomalous
dispersion analysis of a A49 12 crystal soaked with potassium
dicyanoaurate(I). This initial model was used to solve the struc-
tures of full-length A49 and 12 A49 in two distinct crystal
forms bymolecular replacement, whichwere refined as listed in
Table 2.
The structure of A49 12 is presented in Fig. 1, comprising
A49 residues 13–162. Strikingly, despite a lack of sequence con-
servation with known family members, A49 adopts the Bcl-2
family protein fold comprising five -helices wrapped around a
central helix, 5 (45). A search of the PDB using the PDBe-
FOLD server (46) with A49 as a query identified myxoma virus
(MYXV) protein M11 as the closest homologue (3.2 Å root
mean square deviation over 92 C atoms), despite the fact that
the aligned residues share only 8% sequence identity. Whereas
helices 1, 2, and 5 of A49 andM11 overlay well, helices 3,
4 and 6 are significantly rotated in A49 compared with their
orientations inM11 (Fig. 2A). As in VACVprotein F1, the Bcl-2
domain of A49 is preceded by an additional helix (0), but
unlike F1, where 0 extends away from the Bcl-2 domain (15),
in A49 this helix packs tightly against helices 2 and 7 (Fig. 1).
Single turns of the 310 helix immediately follow helices 0 and
4. As with other poxvirus Bcl-2 family proteins, A49 has a
single long C-terminal helix (7) rather than two shorter heli-
ces (47), but unlike other poxvirus Bcl-2 proteins, 7 lies paral-
lel to 0 and its C-terminal residues contact residues at the C
terminus of 2 (Fig. 1).
The structure of full-length A49 closely resembles that of the
truncated protein, superposing on A49 12 with 0.50–0.67 Å
root mean square deviation across 140 C atoms. In the full-
length structure, residues 1–17 could not be modeled due to a
lack of interpretable electron density N-terminal to residue 18.
It is possible that these amino acids were removed by serendip-
itous in-drop proteolysis prior to crystallization. Residues
13–17 adopt three distinct conformations in the 10 A49 12
molecules observed in the two crystal forms (Fig. 1A, inset) and
are disordered in one of the two molecules of A49 12 per
asymmetric unit in crystals grown in the sodiummalonate con-
dition. The only other significant difference between the struc-
tures of full-length and 12 A49 is the conformation of the
TABLE 1
Data collection
Values for the highest resolution shell are in parentheses.
Full-length A49
A49 12
(ammonium sulfate)
A49 12
(sodiummalonate)
A49 12
(gold derivative)a
Beamline ESRF ID14-2 Diamond I04-1 Diamond I04-1 Diamond I04-1
Wavelength (Å) 0.933 0.920 0.920 0.920
Resolution limits (Å) 50.0-3.0 (3.05-3.00) 45.7-1.8 (1.89-1.84) 33.0-1.9 (1.95-1.90) 27.7-1.7 (1.69-1.65)
Space group P43212 P21 P21 P21
Cell dimensions
a, b, c (Å) 67.8, 67.8, 153.9 92.3, 45.6, 160.3 56.9, 42.7, 67.2 79.9, 38.8, 96.9
, ,  (degrees) 90.0, 90.0, 90.0 90.0, 98.7, 90.0 90.0, 100.5, 90.0 90.0, 101.4, 90.0
Unique reflections 7753 (365) 112,855 (8107) 25,211 (1842) 70,769 (5232)
Redundancy 13.8 (14.4) 6.8 (6.6) 14.1 (13.5) 24.8 (12.9)
Completeness (%) 100.0 (100.0) 97.9 (96.0) 99.6 (99.0) 99.9 (99.9)
I/(I)	 17.5 (2.2) 13.6 (1.5) 32.2 (2.9) 20.8 (1.9)
CC1⁄2 1.000 (0.803) 0.999 (0.719) 1.000 (0.920) 1.000 (0.696)
Rmerge 0.101 0.068 (1.160) 0.038 (1.154) 0.127 (1.470)
Rpim 0.045 (0.566) 0.028 (0.483) 0.014 (0.452) 0.024 (0.420)
a Single-wavelength anomalous dispersion phasing statistics were as follows. SHARP figures of merit for centrics/acentrics were 0.156/0.339 (27.66–1.65 Å), 0.191/0.645
(27.66–7.14 Å), and 0.152/0.169 (1.69–1.65 Å). SHARP anomalous phasing power for acentrics was 0.970 (27.66–1.65 Å), 2.984 (27.66–7.14 Å), and 0.217 (1.69–1.65 Å).
Figures of merit after solvent flattening were 0.88 (94.97–1.65 Å), 0.913 (94.97–4.48 Å), and 0.814 (1.68–1.65 Å).
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region linking helices 2 and 3, helix 3 being one turn
shorter in the full-length structure. In four of the eight mole-
cules ofA4912 grown in the ammoniumsulfate condition and
bothmolecules of A4912 grown in the sodiummalonate con-
dition, a single residue (Gly) of theC-terminal purification tag is
observed; in the structure of full-length A49, the final two res-
idues (161 and 162) and the purification tag were not ordered
and could not be modeled.
Unlike M11, A49 Does Not Bind Effector BH3 Peptides—A
characteristic feature of antiapoptotic Bcl-2-like proteins is
their ability to bind amphipathic BH3 peptides via a hydropho-
bic surface groove delineated by helices 2, 3, 4, and 5 (17).
MYXV M11 is a Bcl-2-like protein that inhibits host-cell apo-
ptosis by binding the effector BH3 peptides of proapoptotic
Bcl-2 family proteins Bax and Bak (14, 48). Superposition of
A49 onto the structure of M11 shows that the positions of heli-
TABLE 2
Refinement Statistics
Values for the highest resolution shell are in parentheses.
Full-length A49
A49 12
(ammonium sulfate)
A49 12
(sodiummalonate)
PDB ID 4D5S 4D5T 4D5R
Resolution limits (Å) 154.0-3.0 (3.08-3.00) 45.7-1.8 (1.89-1.84) 33.0-1.9 (1.95-1.90)
Molecules per asymmetric unit 2 8 2
No. of reflections in working set 7350 (532) 107,126 (7671) 23,928 (1744)
No. of reflections in test set 356 (24) 5665 (414) 1279 (89)
Rwork 0.220 (0.358) 0.206 (0.332) 0.185 (0.298)
CCwork 0.967 (0.732) 0.964 (0.781) 0.974 (0.891)
Rfree 0.273 (0.323) 0.239 (0.350) 0.226 (0.286)
CCfree 0.952 (0.771) 0.952 (0.772) 0.959 (0.902)
CC*a 1.000 (0.944) 1.000 (0.915) 1.000 (0.979)
No. of atoms
Protein 2292 10,096 2442
Water 0 894 85
Other 0 25 0
No. of atoms with alternate conformations 0 764 86
Residues in Ramachandran favored region (%) 91.8 98.6 96.0
Ramachandran outliers (%) 0.7 0.0 0.3
Root mean square deviation
Bond length (Å) 0.012 0.017 0.018
Bond angle (degrees) 1.370 1.689 1.749
Average B factor (Å2)
Protein 95.0 37.3 62.9
Water 42.6 59.0
Other 43.3
a CC*
(2CC1⁄2/(1CC1⁄2)) (see Ref. 84).
FIGURE 1. A49 adopts a Bcl-2-like fold. A, the structure of A49 12 is shown in two orthogonal views as a ribbon colored from blue (N terminus) to red (C
terminus). The inset shows the alternative conformations of residues 13–17 observed, highlighting the mobility of this region. In crystals of A49 grown from
full-length protein, no density was observed for these residues. B, sequence of VACV WR A49. The secondary structure is shown above the sequence, and
residues thought to interact with the -propeller domain of -TrCP are in boldface type.
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ces 2–5 are generally conserved between the two proteins
(Fig. 2A). A simple model of A49 bound to a BH3 peptide was
generated by superposingA4912 onto the structure ofM11 in
complex with the Bak BH3 peptide (14). As shown in Fig. 2, B
and C, although a deep groove is evident on the surface of A49
flanked by helices 2–5, it is not compatible with the binding
of BH3 peptides. The side chain of Bak residue Leu78 would
clash with the charged side chains of A49 residues Lys97 and
Asp111. Bak residue Leu78 interacts with a hydrophobic patch
on the M11 surface, is absolutely conserved across BH3 pep-
tides (49) and is essential for strong interaction between BH3
peptides and Bcl-2 family proteins (50). More strikingly, the
orientation of A49 helix 7 shortens the groove such that Bak
residues 80–90, including a conserved aspartic acid and hydro-
phobic residue (Asp83 and Ile85 in Bak, respectively), would
clash with A49. Additionally, helix 4 is rotated in A49 relative
to its orientation in M11 such that A49 residue Asp92 would
clash with Bak Met71.
Co-immunoprecipitation experiments confirmed the inabil-
ity of A49 to bind BH3 peptides of the proapoptotic proteins
Bax and Bak (Fig. 2D). HA-tagged Bax and Bak are co-immu-
noprecipitated from HEK293T cells by an anti-FLAG affinity
matrix when co-expressed with FLAG-taggedM11. These pro-
teins are not co-immunoprecipitated from cells expressing
nTAP-A49, where the A49 protein is Strep-tag II- and FLAG-
tagged. Concomitant infection by VACV lacking an endoge-
nous A49R gene (vA49) does not stimulate co-immunopre-
cipitation of Bax or BakwithA49, confirming that no other viral
factor is required for their interaction. Myc--TrCP is co-im-
munoprecipitatedwith nTAP-A49, confirming that nTAP-A49
is functional (5) and is not co-immunoprecipitated with FLAG-
M11, confirming the specificity of the interaction between A49
and -TrCP.
A49 Does Not Dimerize in Solution or in Cells—A conserved
feature of the VACV Bcl-2-like proteins is their propensity to
formdimers; all VACVBcl-2 family proteins except forK7 crys-
tallize as dimers (11–13, 15, 51, 52). Visual inspection of the
structures of A49 12 and full-length A49 showed that, in all
cases, two molecules of A49 self-associate via an interaction of
helices 4 and 6 (the “4-6 face”; Fig. 3A). In the structure of
full-length A49 this interaction is formed by crystallographic
2-fold symmetry, whereas in the structures of A49 12 the
interaction is formed by pseudo-2-fold non-crystallographic
symmetry. The 4-6 face that mediates the interaction com-
prises a large patch of hydrophobic residues surrounded by a
ring of charged andpolar amino acids (Fig. 3,B andC).Whereas
the self-association is predominantly hydrophobic in nature, in
the structure of full-length A49 a symmetric salt bridge is
formed at the periphery of the binding surface between the side
chains of Arg136 and Asp92. In the structures of A49 12 salt
bridges Arg136–Asp92 and Lys103–Asp139 are formed, although
these bonds are not symmetric and thus formed only once per
pair of A49 molecules. In A49 12 hydrogen bonds are formed
between the side chains of Asn88 and Tyr102 and the carbonyl
oxygens of Thr128 and Val95, respectively, and between the side
chains of Arg136 and Asn96, although again these interactions
often occur only once per pair of A49molecules. Analysis of the
A49 structures using PDBePISA suggested that this 4-6 face
plays an essential role in A49 self-association (CSS scores 0.5–
1.0) (53). However, previous studies of VACV B14 showed that
the self-association interface observed in crystallo was only of
modest affinity in vitro and overlapped with the interface that
mediates the interaction between B14 and IB kinase  (IKK)
in cells (54). We therefore sought to determine the oligomeric
state of A49. SEC-MALS of full-length A49 and A49 12 pro-
duced in bacteria showed that both are monomeric across a
FIGURE 2. A49 lacks a surface groove and does not bind BH3 peptides. A,
the structures of MYXV M11 (blue ribbons, PDB 2JBY (14)) and VACV A49 (yel-
low ribbons) are shown, superposed, in twoorthogonal views. Selectedhelices
are labeled. B, the structure of the human Bak BH3 peptide (green ribbon and
side chains) bound toM11 (bluemolecular surface) is shown (PDB2JBY (14)).C,
model of A49 in complex with the human Bak BH3 peptide generated by
superposing A49 onto theM11-Bak complex (14).Asterisksdenote significant
clashes. D, unlike M11, A49 does not co-immunoprecipitate with human Bak
or Bax. HEK293T cells were transfected with Myc--TrCP (lanes 5 and 8), HA-
Bak (lanes 1, 2, and 6), or HA-Bax (lanes 3, 4, and 7) and nTAP-A49 (lanes 1–5) or
FLAG-M11 (lanes 6–8). After 24 h, cells were infectedwith vA49 at 5 pfu/cell
(lanes 2 and 4) ormock-infected (lanes 1, 3, and 5–8). Cells were lysed 6 h after
infection, and lysateswere immunoprecipitated (IP) with an anti-FLAGmatrix
before immunoblotting using the antibodies specified. Tubulin served as a
loading control, andD8, a VACVenvelopeprotein, served as apositivemarker
of infection.
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range of concentrations (8.6–95.1 M), whereas at even the
lowest concentration tested (7.9 M), VACV N1 is exclusively
dimeric (Fig. 3D). To test whether A49 can self-associate in
cells, HEK293T cells were transfected with nHis-A49 and then
infected with vA49-cTAP, where the A49 protein is Strep-tag
II- and FLAG-tagged. Following incubation of cell lysate with
an anti-FLAG matrix, co-immunoprecipitation of nHis-A49
with A49-cTAP was not observed (Fig. 3E, lane 3). A49-cTAP
and nHis-A49 co-immunoprecipitated with Myc--TrCP and
TAP--TrCP, respectively, confirming that bothA49 alleles are
functional (Fig. 3E, lanes 1 and 2). Under the same conditions,
HA-tagged B14 co-immunoprecipitates with FLAG-B14 (Fig.
3E, lane 4) despite the affinity of the B14 self-association being
relatively modest (20 M) (54). B14-HA does not co-immu-
noprecipitate with A49-cTAP, confirming the specificity of the
B14 self-association (Fig. 3E, lane 5). These data indicate that,
although crystallized A49 self-associates via the 4-6 face, the
protein does not form dimers either in solution or in cells.
Relationship of A49 to Viral and Cellular Bcl-2 Family
Proteins—Exhaustive searches of theNCBI nr (non-redundant)
protein sequence database using PHMMER (55) and
HHSENSER (56) yielded homologues of A49 only in orthopox-
viruses and Yoka poxvirus. The genes encoding A49 homo-
logues in ectromelia virus, taterapox virus, monkeypox virus,
and camelpox virus are all severely truncated and predicted to
not give rise to functional proteins. Among other orthopoxvi-
ruses A49 is well conserved, all sequences sharing94% iden-
tity with A49 from VACV WR, and the residues of the N pep-
tide predicted to interact with-TrCP are absolutely conserved
(5). The A49 homologue in Yoka poxvirus shares 33% identity
with VACV WR A49. Yoka poxvirus A49 has 13 amino acids
N-terminal to helix 0, but the sequence of this region differs
significantly from that of VACVWR A49.
The three-dimensional structures of distantly related pro-
teins are more highly conserved than their amino acid
sequences (57). Given the high sequence divergence between
A49 and other poxvirus Bcl-2-like proteins, we wondered
whetherA49was structurally closer to poxvirus, herpesvirus, or
cellular Bcl-2 family proteins. A representative set of 23 cellular,
5 herpesvirus, and 7 poxvirus Bcl-2 family protein structures,
solved in the presence or absence of protein binding partners,
was assembled and then aligned and clustered by iterative pair-
wise comparison of their structural and physicochemical prop-
erties as described previously (38). Briefly, pairwise comparison
of structures was used to identify the set of equivalent residues
that defines their common structural “core,” and the two most
FIGURE3.A49doesnotoligomerize in solutionor in cells.A, twomolecules of A4912,which interact via helices4 and6 (the “4-6 face”) are shown in two
orthogonal views, colored as in Fig. 1A. B, the 4-6 face of A49 12, with side chains of residues that form the homotypic contact surface shown as sticks. C,
molecular surface representation of the A49 12 4-6 face colored by amino acid hydrophobicity from white (polar) to green (hydrophobic). D, SEC-MALS of
full-length A49 (top), A4912 (middle), and N1 (bottom), each analyzed at three concentrations. Weight-averagedmolarmasses (colored solid lines) are shown
across the elution profiles (normalized differential refractive index, colored dashed lines). The expectedmolarmasses formonomers anddimers of each protein
are shown (gray dotted lines). E, A49 does not self-associate in cells. HEK293T cells were transfectedwith TAP-tagged (lane 1) orMyc-tagged (lane 2)-TrCP and
nHis-A49 (lanes 1 and 3) or FLAG-B14 (lane 4). After 24 h, cells were mock-infected (lane 1) or infected with vA49-cTAP (lanes 2 and 3) or vB14-HA (lane 4) at 2
pfu/cell or co-infectedwith both viruses at 1.5 pfu for each virus per cell (lane 5). Cells were lysed 16 h after infection, and lysateswere immunoprecipitated (IP)
with an anti-FLAG matrix before immunoblotting using the antibodies specified. Tubulin served as a loading control, and D8 served as a positive marker of
infection.
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closely related structures (or structural cores) were merged.
This process was repeated until only one core was left, produc-
ing the hierarchical clustering of structural similarity shown in
Fig. 4A and identifying the minimal set of amino acid residues
that defines the Bcl-2 fold. This minimal core, comprising 56
residues, spans the majority of helices 1, 2, and 5 but also
comprises elements of 3, 6 and 7 (Fig. 4B, inset). All struc-
tures were aligned upon this minimal core and all-pairs pair-
wise comparison of the structures was performed as described
previously (38) to generate the phylogenetic tree shown in Fig.
4B. Strikingly, despite the lack of sequence conservation, the
structures of poxvirus Bcl-2 family proteins, including A49,
more closely resemble each other than they do cellular or her-
pesvirus Bcl-2-like proteins, consistent with previous analysis
of the poxvirus proteins A52, B14, M11, and N1 (13). A49 lies
closest on the tree to MYXVM11 and VACVN1. Both N1 and
M11 bind BH3 peptides and inhibit apoptosis (12, 18, 48),
although N1 does so only weakly compared with other VACV
antiapoptotic proteins (58). The other VACV proteins that
inhibit cellular innate immune responses (A52, K7, B14, and
A46) all cluster together despite having a diverse range of cel-
lular binding partners (12, 13, 59–63). This is in contrast to
cellular Bcl-2 proteins, where orthologues that share a function
lie closer to each other on the tree than paralogues from the
same species with different functions. Overall, the cellular pro-
teins partition away from the virus proteins with the exception
of Bid, which falls between the herpesvirus and poxvirus Bcl-2
proteins. Bid is unlike other cellular Bcl-2 family proteins in
that it has only one Bcl-2 homology domain, BH3, and cleavage
of Bid changes its conformation to promote apoptosis (64–66).
Because its structure is highly divergent from both cellular and
viral Bcl-2 proteins (Fig. 4A), its position in the tree probably
arises from “long branch attraction” (67) rather than greater
structural similarity to viral Bcl-2 proteins.
DISCUSSION
We expressed recombinant VACV A49 and solved its struc-
ture to 1.8 Å resolution (Fig. 1). Surprisingly, A49 adopts a Bcl-
FIGURE 4.Poxvirus Bcl-2 proteins are structurally closer to each other than to other cellular or viral Bcl-2 proteins.A, clustering of cellular and viral Bcl-2
proteins to determine the minimal structural “core” of the Bcl-2 fold. PDB identifiers of structures used are shown as leaves on the tree, colored by source
organism (black, cellular; magenta, herpesvirus; blue, poxvirus). C atom root mean square deviation (Å) and number of equivalent C atoms, which corre-
sponds to the size of the common core, are shown at each branch point. For higher branches in the tree, superpositions were performed between these
common cores to iteratively determine the minimal core of the Bcl-2 fold. B, structure-based phylogenetic tree showing the relationship between cellular,
herpesvirus, and poxvirus Bcl-2 proteins. PDB codes for each structure used are givenwith their species of origin in parentheses (human (H), mouse (M), rat (R),
Caenorhabditis elegans (C), Schistosoma japonicum (SJ), vaccinia virus (VACV), myxoma virus (MYXV), Kaposi sarcoma herpesvirus (KSHV), murine -herpesvirus
68 (MHV-68), and Epstein-Barr virus (EBV)). Structures determined by x-ray crystallography are labeled in black, NMRmodels are shown in gray, and structures
determined with BH3 peptides or C-terminal tails bound in the surface groove are italicized. Ribbon diagrams of representative structures for each protein are
shown, color-ramped from blue (N terminus) to red (C terminus). The inset shows the 56 C atoms that comprise the minimal core of the Bcl-2 fold, colored as
above. Coordinate files containing the core C atoms of the Bcl-2 fold plus superpositions of the 35 representative Bcl-2 family structures upon this core are
supplied as supplemental material.
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2-like fold, despite lacking identifiable sequence similarity with
other members of the Bcl-2 family. The defining characteristic
of cellular Bcl-2 family proteins is their involvement in the reg-
ulation of apoptosis. Intrinsic apoptosis is triggered when the
proapoptotic Bcl-2 family effector proteins Bak and Bax
oligomerize and permeabilize the outer mitochondrial mem-
brane, leading to an irreversible caspase cascade and cell death
(17). Antiapoptotic Bcl-2 proteins oppose apoptosis via a sur-
face groove formed by helices 2–5. This groove binds to the
exposed BH3 peptides of activated Bax or Bak, preventing their
oligomerization. The groove also binds the BH3 peptides of
BH3-only proteins like Bim, sequestering such peptides and
thereby preventing them from binding to and activating Bax or
Bak (17).MXYVproteinM11 andVACVproteinsN1 and F1 all
adopt the Bcl-2 fold and inhibit apoptosis by binding BH3 pep-
tides via a groove on their surface formed by helices 2–5 (12,
14, 15, 18). The A49 structure shows that A49 lacks a surface
groove compatible with binding BH3 peptides and is unable to
bind the proapoptotic proteins Bax or Bak (Fig. 2). This indi-
cates that unlike M11, its closest structural relative, A49 does
not function to inhibit apoptosis by sequestering effector BH3
peptides.
A49 inhibits NF-B activation by inhibiting ubiquitination
and subsequent degradation of IB (5). A49 achieves this by
sequestering the E3 ligase -TrCP, preventing it from binding
the phosphorylated form of IB. The interactionwith-TrCP
requires A49 residues 6–12 (5), which contain a double serine
motif that is likely to be phosphorylated and bind the -propel-
ler domain of -TrCP in an extended conformation similar to
that observed in the complex of -TrCP with -catenin (5, 8).
In the structure of full-lengthA49,we did not observe any inter-
pretable electron density N-terminal to residue 18, nor did we
observe “additional” electron density anywhere in the structure
that could be interpreted as residues 1–17. Additionally, we
observed that A49 crystallized much more readily upon
removal of residues 1–12. These observations indicate that the
N-terminal -TrCP-binding residues of A49 lack intrinsic
structure and are thus freely available to bind -TrCP. How-
ever, we note that residues Ser7 and Ser12 of full-length A49
produced in E. coli are unlikely to have been phosphorylated,
which may possibly influence the conformation of this region.
The HIV-1 immunomodulatory protein Vpu functions sim-
ilarly to A49, binding -TrCP and preventing degradation of
IB (68). However, Vpu also binds the HIV cell surface recep-
tor CD4 and the restriction factor tetherin, promoting their
ubiquitination and degradation by bringing them in close prox-
imity to the SCF-TrCP E3 ligase complex (69, 70). Although a
cellular target of A49-mediated proteasomal or lysosomal deg-
radation has yet to be identified, inspection of the A49 crystal
structures identified a surface of the protein that is a prime
candidate for mediating such interactions. In all crystal forms
presented here the two molecules of A49 self-associate via a
symmetric interaction between helices4 and6 (the 4-6 face).
This interaction is similar to the self-association observed in
crystals of VACV A46 (51) but, unlike A46, A49 does not form
dimers in solution or in cells (Fig. 3). Inspection of the 4-6 face
reveals a hydrophobic surface cleft that would seem ideal for
mediating interactions with cellular binding partners (Fig. 3).
Dimerization of VACV proteins in crystallo by surfaces that
mediate binding to cellular partners has been observed before;
the 1-6 face of B14 that mediates its reversible self-association
in solution overlaps with its binding site for IKK (54), muta-
tions that abolish dimerization of N1 also disrupt its ability to
inhibit NF-B activation (18), and a residue of A52 required for
binding to TRAF6 lies partly buried within the dimerization
interface (71), although in this case maintaining A52 dimeriza-
tion seems to be required for efficient TRAF6-mediated stimu-
lation of p38 and subsequent induction of IL-10 expression. It is
tempting to speculate that A49 binds other cellular factors via
the 4-6 face to promote their -TrCP-mediated ubiquitination
and degradation, although further experiments are required to
probe this hypothesis.
The structure of A49 takes to 11 the number of VACV pro-
teins that have been shown or predicted to share the Bcl-2 fold
(Table 3). Although the bulk of poxvirus Bcl-2 proteins share
weak but identifiable sequence similarity (16, 72), A49 could
not be identified as a Bcl-2 family protein based on sequence
alone. Nonetheless, structure-based phylogenetic analysis
shows A49 to be more closely related to poxvirus than herpes-
virus or cellular Bcl-2 proteins (Fig. 4). This is consistent with
poxvirus Bcl-2 family proteins having arisen from gene dupli-
cation and divergence following a single gene acquisition event,
structural similarity having been conserved despite vast
sequence divergence. The terminal regions of the poxvirus
genome are highly variable, containing non-essential genes that
act to determine host range and inhibit the host immune
response (2). In addition to terminal transpositions, whereby
genes from one end of the linear genome are duplicated at the
other end (72–74), a recent study showed that poxviruses
deploy “genomic accordions” when under selective pressure,
their genomes rapidly expanding to incorporate multiple cop-
ies of genes near points of genomic instability (75). This expan-
sion increases the probability that duplicated genes will acquire
“advantageous” mutations, potentially conferring a divergent
function upon the mutated gene. The host innate immune
response places large DNA viruses under significant selective
pressure (76), and poxvirus Bcl-2 family proteins all act to
inhibit the cellular responses to infection. Inspection of the low
frequency duplications observed in the Copenhagen strain of
VACV (or strains derived therefrom) (75) show independent
gene duplications encompassing several Bcl-2 family proteins:
the duplicated VACV Copenhagen region spanning nucleo-
TABLE 3
VACV proteins with a Bcl-2-like fold
Proteina Function References
C16/B22 Unknown 13
C6 Inhibition of IRF3 and IRF7 13, 77
C1 Unknown 16
N1 Inhibition of NF-B and apoptosis 11, 12, 63
N2 Inhibition of IRF3 16, 78
K7 Inhibition of NF-B and IRF3 13, 62, 79
F1 Inhibition of apoptosis and IL-1 production 15, 80–82
A46 Inhibition of MAPKs, NF-B and IRF3 13, 51, 61, 83
A49 Inhibition of NF-B 5, this study
A52 Inhibition of NF-B and stimulation of p38 MAPK 13, 60, 71, 83
B14b Inhibition of NF-B 13, 59
a Protein names are for VACV strain Copenhagen except as noted.
b Encoded by VACVWR gene B14R, which is equivalent to VACV Copenhagen
gene B15R (22).
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tides 143,153–156,405 contains A46 and A49; the duplicated
region spanning nucleotides 22,298–29,837 contains C1, N1,
and N2; and the duplicated regions spanning nucleotides
24,975–47,387 or 25,066–47,467 contain N1, K7, and F1. This
is consistent with the gene duplication and differentiation
events that gave rise to the 11 VACV Bcl-2 family immuno-
modulatory proteins having arisen as a result of ancestral pox-
viruses deploying their genomic accordions in response to
selective pressure generated by adaptation in the host or
changes in host range. Although A49 has high sequence diver-
gence from the other poxvirus Bcl-2 proteins, its absence from
Yata-, Lepri-, Sui-, Cervid-, or Capripoxviruses, all of which
have multiple Bcl-2 like proteins, makes it a poor candidate for
being the BCL2 gene acquired originally by the ancestral
poxvirus.
In summary, we have shown that A49 is an unanticipated
eleventh member of the VACV Bcl-2-like immunomodulatory
protein family. A49 lacks a BH3 peptide binding groove and
does not bind the proapoptotic proteins Bax and Bak. Although
A49 self-associates via a hydrophobic 4-6 face in crystals, it does
not self-associate in solution or in cells, suggesting that this 4-6
face may mediate binding to yet undetermined cellular part-
ners. Conservation of the Bcl-2 fold by poxvirus proteins with
highly divergent sequences is consistent with duplication and
divergence of an ancestral gene encoding a Bcl-2 family protein.
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